New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.
Scott T. Aaronson, Zofia Kozak
Med (New York, N.Y.) March 8, 2024 DOI: 10.1016/j.medj.2024.01.014 via PubMed
Summary
AI-generated from the abstractA flexible dosing schedule of psilocybin is feasible for individuals with severely treatment-resistant depression, including those with co-morbid conditions or bipolar II disorder, potentially expanding who can receive this treatment. The trial by Rosenblat et al. demonstrates that such patients, previously excluded from studies, can safely participate, suggesting a broader application of psilocybin therapy for complex depression cases.
Study at a glance
| Characteristics | Clinical trial Peer reviewed |
|---|---|
| Population | Individuals with severely treatment-resistant depression, including those with co-morbid conditions or bipolar II disorder |
| Intervention | Psilocybin |
| Dose | flexible dosing schedule |
| Topics | Depression Psychedelic-assisted therapy |
| Keywords | Personalized medicine Depression treatment Mental health research |
| Citations | 1 |
| Key finding | A flexible dosing schedule of psilocybin is feasible in individuals with severely treatment-resistant depression, including those with co-morbid conditions or bipolar II disorder. |
Abstract
Psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. A recent clinical trial by Rosenblat at al.1 demonstrates feasibility of a flexible dosing schedule of psilocybin in individuals with severely treatment-resistant depression (TRD), including those with co-morbid conditions or bipolar II disorder (BPII), potentially expanding the current treatment paradigm.